October Update- Upcoming and Recruiting Hepatitis C Clinical Trials

Upcoming and Recruiting Hepatitis C Clinical Trials

The HCV clinical trials in this post are not a complete list; to learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.

For a quick reference guide of drugs under development and FDA approved medications please visit:

HCV Advocate

Detailed Reference Guide

FDA Approved Medications

Phase II Clinical Trials

Phase III Clinical Trials

Hepatitis C Treatments in Current Clinical Development

Of Interest

The 66th Liver Meeting of the American Association for the Study of Liver Diseases will take place in San Francisco, California between 13th and 17th November 2015, view late breaking abstracts, here. get updates of the meeting on twitter, here, or follow AASLD tweets, here.

This study is currently recruiting participants

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
ClinicalTrials.gov Identifier:
NCT02442284
Conditions: Chronic Hepatitis C; Cirrhosis; Hepatitis C Virus
Interventions: Drug: Ombitasvir; Drug: Paritaprevir; Drug: Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie

Verified October 2015 by AbbVie

This study is currently recruiting participants.

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) 

ClinicalTrials.gov Identifier:
NCT02582658
‎Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified October 2015

New

This study is currently recruiting participants

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
ClinicalTrials.gov Identifier:
NCT02581163

‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C, Genotype 1 or 4
Intervention:
Sponsor: AbbVie
Recruiting - verified October 2015 

This study is currently recruiting participants.

Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

United States, New York, France

ClinicalTrials.gov Identifier:
NCT02493855

Conditions: Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1a
Interventions: Drug: ombitasvir/ABT-450/ritonavir; Drug: dasabuvir; Drug: ribavirin
Verified October 2015 by AbbVie

This study is currently recruiting participants.

China

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
ClinicalTrials.gov Identifier:
NCT02576314

‎Monday, ‎October ‎12, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C Infection
Interventions: Drug: SOF+DCV; Drug: LDV/SOF
Sponsors: Humanity & Healthy GI and Liver Centre; Beijing 302 Hospital
Recruiting - verified October 2015 

This study is currently recruiting participants

India

Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy
ClinicalTrials.gov Identifier:
NCT02563665‎

Saturday, ‎September ‎26, ‎2015, ‏‎12:00:00 PM
Condition: CKD With Hepatitis C
Intervention:
Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting - verified September 2015 

This study is currently recruiting participants

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
ClinicalTrials.gov Identifier:
NCT02442271
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Verified October 2015 by AbbVie

This study is currently recruiting participants

Canada, Belgium
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

ClinicalTrials.gov Identifier:
NCT02421211
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir (SMV); Drug: Ledipasvir (LDV); Drug: Sofosbuvir (SOF)
Sponsor: Janssen Sciences Ireland UC

Verified September 2015

This study is currently recruiting participants

A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection

ClinicalTrials.gov Identifier:
NCT01939197

Conditions: Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhotics
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin (RBV)

Verified October 2015 by AbbVie

This study is currently recruiting participants

New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
United States, Maryland
ClinicalTrials.gov Identifier:
NCT01888900

Verified February 2015 by National Institutes of Health Clinical Center (CC)

Drug: Asunaprevir and Daclatsvir
Drug: Asunaprevir, daclatsvir, peginterferon, ribavirin

This study is not yet open for participant recruitment

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir
ClinicalTrials.gov Identifier:
NCT02569710‎

Thursday, ‎October ‎01, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335; Drug: ACH-3102; Drug: Simeprevir
Sponsor: Alios Biopharma Inc.
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
‎Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM

ClinicalTrials.gov Identifier:
NCT02582632

Conditions: Hepatitis C Infection; Hepatitis C Virus
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: dasabuvir
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

New

This study is not yet open for participant recruitment

The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
ClinicalTrials.gov Identifier:
NCT02582671‎

Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects 

ClinicalTrials.gov Identifier:
NCT02581020
‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus
Intervention:
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
ClinicalTrials.gov Identifier:
NCT02580474‎

Friday, ‎October ‎16, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Intervention: Drug: Daclatasvir plus Asunaprevir
Sponsors: Myeong Jun Song; Bristol-Myers Squibb; Soonchunhyang University Hospital; Dankook University; Chungnam National University Hospital; Konyang University Hospital; Eulji University Hospital; Saint Vincent's Hospital, Korea; Konkuk University Hospital; Cheongju St. Mary's Hospital, Cheongju, Korea; Severance Hospital; Korea University Guro Hospital; Eulji General Hospital
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment

A Drug-drug Interaction Study Between Daclatasvir and Metformin
ClinicalTrials.gov Identifier:
NCT02565862

‎Wednesday, ‎September ‎30, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis C; Diabetes Mellitus; Insulin Resistance
Interventions: Drug: Daclatasvir; Drug: Metformin
Sponsor: Radboud University
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
ClinicalTrials.gov Identifier:
NCT02565888‎

Wednesday, ‎September ‎30, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis C; HIV
Interventions: Drug: Daclatasvir; Drug: Atazanavir; Drug: Ritonavir; Drug: Cobicistat
Sponsor: Radboud University
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
ClinicalTrials.gov Identifier:
NCT02562742

‎Monday, ‎September ‎28, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: SOF; Drug: REB
Sponsors: Gilead Sciences; Merck Sharp & Dohme Corp. Japan
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
ClinicalTrials.gov Identifier:
NCT02556086

‎Tuesday, ‎September ‎15, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: Daclatasvir; Drug: Sofosbuvir
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
ClinicalTrials.gov Identifier:
NCT02551861‎

Tuesday, ‎September ‎15, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: Daclatasvir; Drug: Sofosbuvir; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified September 2015